Catalog Home Page

The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy

Lee, S., Laiman, A., French, M.A, Flexman, J., Watson, M.W. and Price, P. (2017) The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy. Clinical Immunology, 179 . pp. 54-63.

Link to Published Version: http://dx.doi.org/10.1016/j.clim.2017.03.005
*Subscription may be required

Abstract

Antibody responses have not been fully characterised in chronically HIV/HCV patients receiving antiretroviral therapy (ART). Seventeen HIV/HCV patients receiving ART were followed for a median (range) interval of 597 (186–766) weeks. Prior to ART, HIV/HCV patients had lower levels of antibodies reactive with HCV core and JFH-1, and lower genotype cross-reactive neutralising antibodies (nAb) titres, than HCV patients. Levels of JFH-1 reactive antibody increased on ART, irrespective of CD4+ T-cell counts or changes in serum ALT levels. The appearance of nAb coincided with control of HCV viral replication in five HIV/HCV patients. In other patients, HCV viral loads remained elevated despite nAb responses. Sustained virological responses following HCV therapy were associated with reduced antibody responses to JFH-1 and core but elevated responses to non-structural proteins. We conclude that nAb responses alone may fail to clear HCV, but contribute to control of viral replication in some HIV/HCV patients responding to ART.

Publication Type: Journal Article
Murdoch Affiliation: Centre for Clinical Immunology and Biomedical Statistics
Publisher: Academic Press Inc.
Copyright: © 2017 Elsevier Inc.
URI: http://researchrepository.murdoch.edu.au/id/eprint/36287
Item Control Page Item Control Page